What you need to know about the new direct marketing guidance note
Nadine Mather and Chloë Loubser
South African firm signs agreement with leading Indian pharmaceutical group
An agreement undertaken by Litha Pharma, a subsidiary of the Litha Healthcare Group and Gland Pharma, a leading Indian based generic pharmaceutical manufacturer, will see the healthcare group expanding its presence in the injectable generics market.
Located in Hyderabad, India where a number of large biopharmaceutical companies have operations, the company has pioneered heparin technology (anticoagulant technology) in India. The US FDA, UK MHRA, Slovakian authorities, Health Canada, TGA Australia and regulatory authorities in Asia and Latin America have approved the company's syringe, ampoule, infusions and vial filling manufacturing lines.
"Technological innovation has become a key driver for companies in the generic pharmaceutical market, which was a key consideration when entering into the agreement. The company is a supplier of cutting edge injectables, particularly pre-filled syringes," says Litha Healthcare Group CEO, Selwyn Kahanovitz.
"They already supply products to an emerging Indian market and therefore understand the environmental healthcare considerations for the South African market, as well as having a significant amount of their output sold in the US and Europe. To this end, part of the agreement also includes the development of future products tailored for our local market."
